Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma

Introduction Hepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important. Objective To evaluate the serum levels of three inflammation markers in relation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of clinical practice (Esher) 2021-02, Vol.75 (2), p.e13593-n/a
Hauptverfasser: Akkiz, Hikmet, Carr, Brian I., Bag, Harika G., Karaoğullarından, Ümit, Yalçın, Kendal, Ekin, Nazim, Özakyol, Ayşegül, Altıntaş, Engin, Balaban, Hatice Y., Şimşek, Halis, Uyanıkoğlu, Ahmet, Balkan, Ayhan, Kuran, Sedef, Üsküdar, Oğuz, Ülger, Yakup, Güney, Burak, Delik, Anil
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 2
container_start_page e13593
container_title International journal of clinical practice (Esher)
container_volume 75
creator Akkiz, Hikmet
Carr, Brian I.
Bag, Harika G.
Karaoğullarından, Ümit
Yalçın, Kendal
Ekin, Nazim
Özakyol, Ayşegül
Altıntaş, Engin
Balaban, Hatice Y.
Şimşek, Halis
Uyanıkoğlu, Ahmet
Balkan, Ayhan
Kuran, Sedef
Üsküdar, Oğuz
Ülger, Yakup
Güney, Burak
Delik, Anil
description Introduction Hepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important. Objective To evaluate the serum levels of three inflammation markers in relation to survival in HCC patients. Methods We retrospectively examined the serum levels of CRP, albumin and ESR, both singly and in combination, in relation to patient survival. Results Survival worsened with increase in CRP or ESR or decrease in albumin levels. Combinations of CRP plus albumin or CRP plus ESR were associated with an even greater range of survival (3‐fold), together with significant differences in maximum tumor diameter (PVT) and percent of patients with portal vein thrombosis (PVT). The triplet of CRP plus albumin plus ESR was associated with a sevenfold difference in survival, comparing low vs high parameter levels. These significant differences were found in patients with small or large tumors. Conclusions Combinations of CRP with albumin or ESR or all three parameters together significantly related to differences in survival and to differences in MTD and percent PVT, in patients with both small and large size HCCs.
doi_str_mv 10.1111/ijcp.13593
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7758189</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2479584547</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4483-752fa63bc6f80d06ec75bed0bf4b1faef33e310508ce7f0cab08a07d1ad80ce3</originalsourceid><addsrcrecordid>eNp9kU9rFDEYh4MotlYvfgAJeBOnJpNkk70IslStFCxt7-GdzBs3a2ayJjNbFvzwpm4tejGX_Ht48gs_Ql5ydsrreBc2bnvKhVqKR-SYa9k2vJX8cV2LhWkUE_yIPCtlw1irlGFPyZFolRFyKY_Jz2vM80Aj7jAWmjwNo48wDDClvKcD5O-YC11dXb6lZ9dXFMaeQuzmIYyVpBkjTCGNdEq0zHkXdhCpT5lu6zGOU6G3YVrTNdZ9chjjHCFTB9mFMQ3wnDzxEAu-uJ9PyM3Hs5vV5-bi66fz1YeLxklpRKNV62EhOrfwhvVsgU6rDnvWedlxD-iFQMGZYsah9sxBxwww3XPoDXMoTsj7g3Y7dwP2rgbLEO02h_q_vU0Q7L83Y1jbb2lntVaGm2UVvL4X5PRjxjLZTZrzWCPbVuqlMlJJXak3B8rlVEpG__ACZ_auKHtXlP1dVIVf_Z3pAf3TTAX4AbgNEff_UdnzL6vLg_QX6VOiHQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2479584547</pqid></control><display><type>article</type><title>Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Akkiz, Hikmet ; Carr, Brian I. ; Bag, Harika G. ; Karaoğullarından, Ümit ; Yalçın, Kendal ; Ekin, Nazim ; Özakyol, Ayşegül ; Altıntaş, Engin ; Balaban, Hatice Y. ; Şimşek, Halis ; Uyanıkoğlu, Ahmet ; Balkan, Ayhan ; Kuran, Sedef ; Üsküdar, Oğuz ; Ülger, Yakup ; Güney, Burak ; Delik, Anil</creator><creatorcontrib>Akkiz, Hikmet ; Carr, Brian I. ; Bag, Harika G. ; Karaoğullarından, Ümit ; Yalçın, Kendal ; Ekin, Nazim ; Özakyol, Ayşegül ; Altıntaş, Engin ; Balaban, Hatice Y. ; Şimşek, Halis ; Uyanıkoğlu, Ahmet ; Balkan, Ayhan ; Kuran, Sedef ; Üsküdar, Oğuz ; Ülger, Yakup ; Güney, Burak ; Delik, Anil</creatorcontrib><description>Introduction Hepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important. Objective To evaluate the serum levels of three inflammation markers in relation to survival in HCC patients. Methods We retrospectively examined the serum levels of CRP, albumin and ESR, both singly and in combination, in relation to patient survival. Results Survival worsened with increase in CRP or ESR or decrease in albumin levels. Combinations of CRP plus albumin or CRP plus ESR were associated with an even greater range of survival (3‐fold), together with significant differences in maximum tumor diameter (PVT) and percent of patients with portal vein thrombosis (PVT). The triplet of CRP plus albumin plus ESR was associated with a sevenfold difference in survival, comparing low vs high parameter levels. These significant differences were found in patients with small or large tumors. Conclusions Combinations of CRP with albumin or ESR or all three parameters together significantly related to differences in survival and to differences in MTD and percent PVT, in patients with both small and large size HCCs.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/ijcp.13593</identifier><identifier>PMID: 32583494</identifier><language>eng</language><publisher>England: Hindawi Limited</publisher><subject>Albumin ; Albumins ; Biomarkers ; C-Reactive Protein ; Carcinoma, Hepatocellular ; Hepatocellular carcinoma ; Humans ; Inflammation ; Liver cancer ; Liver Neoplasms ; Portal vein ; Retrospective Studies ; Serum levels ; Survival ; Thrombosis ; Tumors</subject><ispartof>International journal of clinical practice (Esher), 2021-02, Vol.75 (2), p.e13593-n/a</ispartof><rights>2020 John Wiley &amp; Sons Ltd</rights><rights>2020 John Wiley &amp; Sons Ltd.</rights><rights>Copyright © 2021 John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4483-752fa63bc6f80d06ec75bed0bf4b1faef33e310508ce7f0cab08a07d1ad80ce3</citedby><cites>FETCH-LOGICAL-c4483-752fa63bc6f80d06ec75bed0bf4b1faef33e310508ce7f0cab08a07d1ad80ce3</cites><orcidid>0000-0002-0901-9192 ; 0000-0002-6111-5077</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijcp.13593$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijcp.13593$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32583494$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akkiz, Hikmet</creatorcontrib><creatorcontrib>Carr, Brian I.</creatorcontrib><creatorcontrib>Bag, Harika G.</creatorcontrib><creatorcontrib>Karaoğullarından, Ümit</creatorcontrib><creatorcontrib>Yalçın, Kendal</creatorcontrib><creatorcontrib>Ekin, Nazim</creatorcontrib><creatorcontrib>Özakyol, Ayşegül</creatorcontrib><creatorcontrib>Altıntaş, Engin</creatorcontrib><creatorcontrib>Balaban, Hatice Y.</creatorcontrib><creatorcontrib>Şimşek, Halis</creatorcontrib><creatorcontrib>Uyanıkoğlu, Ahmet</creatorcontrib><creatorcontrib>Balkan, Ayhan</creatorcontrib><creatorcontrib>Kuran, Sedef</creatorcontrib><creatorcontrib>Üsküdar, Oğuz</creatorcontrib><creatorcontrib>Ülger, Yakup</creatorcontrib><creatorcontrib>Güney, Burak</creatorcontrib><creatorcontrib>Delik, Anil</creatorcontrib><title>Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma</title><title>International journal of clinical practice (Esher)</title><addtitle>Int J Clin Pract</addtitle><description>Introduction Hepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important. Objective To evaluate the serum levels of three inflammation markers in relation to survival in HCC patients. Methods We retrospectively examined the serum levels of CRP, albumin and ESR, both singly and in combination, in relation to patient survival. Results Survival worsened with increase in CRP or ESR or decrease in albumin levels. Combinations of CRP plus albumin or CRP plus ESR were associated with an even greater range of survival (3‐fold), together with significant differences in maximum tumor diameter (PVT) and percent of patients with portal vein thrombosis (PVT). The triplet of CRP plus albumin plus ESR was associated with a sevenfold difference in survival, comparing low vs high parameter levels. These significant differences were found in patients with small or large tumors. Conclusions Combinations of CRP with albumin or ESR or all three parameters together significantly related to differences in survival and to differences in MTD and percent PVT, in patients with both small and large size HCCs.</description><subject>Albumin</subject><subject>Albumins</subject><subject>Biomarkers</subject><subject>C-Reactive Protein</subject><subject>Carcinoma, Hepatocellular</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Liver cancer</subject><subject>Liver Neoplasms</subject><subject>Portal vein</subject><subject>Retrospective Studies</subject><subject>Serum levels</subject><subject>Survival</subject><subject>Thrombosis</subject><subject>Tumors</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9rFDEYh4MotlYvfgAJeBOnJpNkk70IslStFCxt7-GdzBs3a2ayJjNbFvzwpm4tejGX_Ht48gs_Ql5ydsrreBc2bnvKhVqKR-SYa9k2vJX8cV2LhWkUE_yIPCtlw1irlGFPyZFolRFyKY_Jz2vM80Aj7jAWmjwNo48wDDClvKcD5O-YC11dXb6lZ9dXFMaeQuzmIYyVpBkjTCGNdEq0zHkXdhCpT5lu6zGOU6G3YVrTNdZ9chjjHCFTB9mFMQ3wnDzxEAu-uJ9PyM3Hs5vV5-bi66fz1YeLxklpRKNV62EhOrfwhvVsgU6rDnvWedlxD-iFQMGZYsah9sxBxwww3XPoDXMoTsj7g3Y7dwP2rgbLEO02h_q_vU0Q7L83Y1jbb2lntVaGm2UVvL4X5PRjxjLZTZrzWCPbVuqlMlJJXak3B8rlVEpG__ACZ_auKHtXlP1dVIVf_Z3pAf3TTAX4AbgNEff_UdnzL6vLg_QX6VOiHQ</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Akkiz, Hikmet</creator><creator>Carr, Brian I.</creator><creator>Bag, Harika G.</creator><creator>Karaoğullarından, Ümit</creator><creator>Yalçın, Kendal</creator><creator>Ekin, Nazim</creator><creator>Özakyol, Ayşegül</creator><creator>Altıntaş, Engin</creator><creator>Balaban, Hatice Y.</creator><creator>Şimşek, Halis</creator><creator>Uyanıkoğlu, Ahmet</creator><creator>Balkan, Ayhan</creator><creator>Kuran, Sedef</creator><creator>Üsküdar, Oğuz</creator><creator>Ülger, Yakup</creator><creator>Güney, Burak</creator><creator>Delik, Anil</creator><general>Hindawi Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0901-9192</orcidid><orcidid>https://orcid.org/0000-0002-6111-5077</orcidid></search><sort><creationdate>202102</creationdate><title>Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma</title><author>Akkiz, Hikmet ; Carr, Brian I. ; Bag, Harika G. ; Karaoğullarından, Ümit ; Yalçın, Kendal ; Ekin, Nazim ; Özakyol, Ayşegül ; Altıntaş, Engin ; Balaban, Hatice Y. ; Şimşek, Halis ; Uyanıkoğlu, Ahmet ; Balkan, Ayhan ; Kuran, Sedef ; Üsküdar, Oğuz ; Ülger, Yakup ; Güney, Burak ; Delik, Anil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4483-752fa63bc6f80d06ec75bed0bf4b1faef33e310508ce7f0cab08a07d1ad80ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Albumin</topic><topic>Albumins</topic><topic>Biomarkers</topic><topic>C-Reactive Protein</topic><topic>Carcinoma, Hepatocellular</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Liver cancer</topic><topic>Liver Neoplasms</topic><topic>Portal vein</topic><topic>Retrospective Studies</topic><topic>Serum levels</topic><topic>Survival</topic><topic>Thrombosis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akkiz, Hikmet</creatorcontrib><creatorcontrib>Carr, Brian I.</creatorcontrib><creatorcontrib>Bag, Harika G.</creatorcontrib><creatorcontrib>Karaoğullarından, Ümit</creatorcontrib><creatorcontrib>Yalçın, Kendal</creatorcontrib><creatorcontrib>Ekin, Nazim</creatorcontrib><creatorcontrib>Özakyol, Ayşegül</creatorcontrib><creatorcontrib>Altıntaş, Engin</creatorcontrib><creatorcontrib>Balaban, Hatice Y.</creatorcontrib><creatorcontrib>Şimşek, Halis</creatorcontrib><creatorcontrib>Uyanıkoğlu, Ahmet</creatorcontrib><creatorcontrib>Balkan, Ayhan</creatorcontrib><creatorcontrib>Kuran, Sedef</creatorcontrib><creatorcontrib>Üsküdar, Oğuz</creatorcontrib><creatorcontrib>Ülger, Yakup</creatorcontrib><creatorcontrib>Güney, Burak</creatorcontrib><creatorcontrib>Delik, Anil</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akkiz, Hikmet</au><au>Carr, Brian I.</au><au>Bag, Harika G.</au><au>Karaoğullarından, Ümit</au><au>Yalçın, Kendal</au><au>Ekin, Nazim</au><au>Özakyol, Ayşegül</au><au>Altıntaş, Engin</au><au>Balaban, Hatice Y.</au><au>Şimşek, Halis</au><au>Uyanıkoğlu, Ahmet</au><au>Balkan, Ayhan</au><au>Kuran, Sedef</au><au>Üsküdar, Oğuz</au><au>Ülger, Yakup</au><au>Güney, Burak</au><au>Delik, Anil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><addtitle>Int J Clin Pract</addtitle><date>2021-02</date><risdate>2021</risdate><volume>75</volume><issue>2</issue><spage>e13593</spage><epage>n/a</epage><pages>e13593-n/a</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Introduction Hepatocellular carcinoma is associated with several chronic inflammatory conditions. It is increasingly understood that the inflammation may be part of the carcinogenic process and prognostically important. Objective To evaluate the serum levels of three inflammation markers in relation to survival in HCC patients. Methods We retrospectively examined the serum levels of CRP, albumin and ESR, both singly and in combination, in relation to patient survival. Results Survival worsened with increase in CRP or ESR or decrease in albumin levels. Combinations of CRP plus albumin or CRP plus ESR were associated with an even greater range of survival (3‐fold), together with significant differences in maximum tumor diameter (PVT) and percent of patients with portal vein thrombosis (PVT). The triplet of CRP plus albumin plus ESR was associated with a sevenfold difference in survival, comparing low vs high parameter levels. These significant differences were found in patients with small or large tumors. Conclusions Combinations of CRP with albumin or ESR or all three parameters together significantly related to differences in survival and to differences in MTD and percent PVT, in patients with both small and large size HCCs.</abstract><cop>England</cop><pub>Hindawi Limited</pub><pmid>32583494</pmid><doi>10.1111/ijcp.13593</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-0901-9192</orcidid><orcidid>https://orcid.org/0000-0002-6111-5077</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1368-5031
ispartof International journal of clinical practice (Esher), 2021-02, Vol.75 (2), p.e13593-n/a
issn 1368-5031
1742-1241
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7758189
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Albumin
Albumins
Biomarkers
C-Reactive Protein
Carcinoma, Hepatocellular
Hepatocellular carcinoma
Humans
Inflammation
Liver cancer
Liver Neoplasms
Portal vein
Retrospective Studies
Serum levels
Survival
Thrombosis
Tumors
title Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T12%3A38%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20levels%20of%20inflammatory%20markers%20CRP,%20ESR%20and%20albumin%20in%20relation%20to%20survival%20for%20patients%20with%20hepatocellular%20carcinoma&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Akkiz,%20Hikmet&rft.date=2021-02&rft.volume=75&rft.issue=2&rft.spage=e13593&rft.epage=n/a&rft.pages=e13593-n/a&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/ijcp.13593&rft_dat=%3Cproquest_pubme%3E2479584547%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2479584547&rft_id=info:pmid/32583494&rfr_iscdi=true